{"protocolSection": {"identificationModule": {"nctId": "NCT00604500", "orgStudyIdInfo": {"id": "P04703"}, "secondaryIdInfos": [{"id": "3462123"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)", "officialTitle": "An Open-Label, Multi-Center, Patient Handling Study of Mometasone Furoate/Formoterol Fumarate MDI With an Integrated Dose Counter in Adolescent and Adult Subjects and Adult With Asthma or COPD"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-03-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-11-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-11-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-21", "studyFirstSubmitQcDate": "2008-01-21", "studyFirstPostDateStruct": {"date": "2008-01-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-07-15", "resultsFirstSubmitQcDate": "2011-03-11", "resultsFirstPostDateStruct": {"date": "2011-04-12", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-08", "lastUpdatePostDateStruct": {"date": "2024-05-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}, "collaborators": [{"name": "Novartis", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This was an open-label, multiple-dose, study of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 micrograms (mcg) twice daily (BID) (2 puffs of MF/F MDI 50/5 mcg, administered twice a day approximately 12 hours apart) in participants 12 years of age or older, with a diagnosis of persistent asthma or chronic obstructive pulmonary disease (COPD) of at least 12 months. The primary purpose of the study was to evaluate the performance of the MF/F MDI integrated dose counter under normal patient handling conditions."}, "conditionsModule": {"conditions": ["Asthma", "COPD"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 272, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MF/F MDI 100/10 mcg BID with dose counter", "type": "EXPERIMENTAL", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.", "interventionNames": ["Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )"]}], "interventions": [{"type": "DRUG", "name": "SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.", "armGroupLabels": ["MF/F MDI 100/10 mcg BID with dose counter"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Overall Discrepancy Rate", "description": "Overall discrepancies refer to the difference between the participant-recorded number of actuations and the participant-recorded dose counter readout across the 4-week Treatment Period. The Overall Discrepancy Rate was calculated as 100 multiplied by the total number of discrepancies across all participants who used at least 90% of the labeled actuations divided by the total number of actuations in the same participant population (Completer Population).", "timeFrame": "4-week Treatment Period"}, {"measure": "Overall Quartile Discrepancy Rate", "description": "Quartile discrepancies refer to the difference between\n\nthe participant-recorded number of actuations and the participant-recorded\n\ncounter readout at each of the 4 weekly visit intervals \\[ie, quartiles\\] to\n\nevaluate whether there was any difference in agreement over the life of\n\nthe inhaler. The Quartile Discrepancy Rate was calculated as 100 multiplied by the total number of discrepancies per Quartile across all participant who used at least 90% of the labeled actuations divided by the total number of actuations per Quartile in the same population.", "timeFrame": "4-week Treatment Period"}, {"measure": "Overall Discrepancy Size", "description": "Discrepancy Size refers to the magnitude of the discrepancy between the dose counter readout and the number of recorded actuations (definition of discrepancy). Overall Discrepancy Size was calculated as 100 multiplied by the sum of the absolute values from each Dose Counter Discrepancy Size across all participants who used at least 90% of the labeled actuations divided by the total number of recorded actuations in the same participant population.", "timeFrame": "4-week Treatment Period"}, {"measure": "End of Use Agreement: Number of Inhalers With an End of Use Agreement of 0 (Completer Population)", "description": "The difference in the final MDI dose counter readout and the total number of recorded actuations at the end-of-use. Dose Counter end-of-use agreement was calculated as the sum of the absolute difference between the final dose counter readout and the number of recorded actuations across all participants who used at least 90% of the labeled actuations (excluding participants who used the inhaler beyond the labeled number of actuations) divided by the total number of participants in this population. No participant used more than two inhalers during the treatment period.", "timeFrame": "4-week Treatment Period"}]}, "eligibilityModule": {"eligibilityCriteria": "Diagnosis and Criteria for Inclusion:\n\n* A participant must have been at least 12 years of age, of either sex, and of any race, with a diagnosis of persistent asthma or COPD of at least 12 months.\n* A participant must have been able to demonstrate correct use of an MDI without a counter at the Screening Visit.\n* A participant must have demonstrated at least 90% compliance with completion of the e-diary, use of the counterstrip, and use of the study medication over the 2-week Screening Period.\n\nExclusion Criteria:\n\n* Participants with a serious uncontrolled medical disorder, which in the judgment of the investigator, could have interfered with the study, or required treatment which might interfere with the study.\n* Participants who in the judgment of the investigator and/or sponsor had a significant recent or current, repetitive strain injury (RSI) that may have impacted their ability to effectively participate in the full duration of the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "referencesModule": {"references": [{"pmid": "21398104", "type": "DERIVED", "citation": "Weinstein C, Staudinger H, Scott I, Amar NJ, LaForce C. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir Med. 2011 Jul;105(7):979-88. doi: 10.1016/j.rmed.2011.01.013. Epub 2011 Mar 12."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MF/F MDI 100/10 mcg BID (With Dose Counter)", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of 50/5 mcg, twice a day) over a 4-week Treatment Period."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "272"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "There were 233 participants who took at least 90% of the labeled actuations (Completer Population).", "numSubjects": "261"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Treatment Failure", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Administrative", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Did not meet protocol eligibility", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MF/F MDI 100/10 mcg BID (With Dose Counter)", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of 50/5 mcg, twice a day) over a 4-week Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "272"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "Age 12 to <18 years of age", "categories": [{"measurements": [{"groupId": "BG000", "value": "14.69", "spread": "1.64"}]}]}, {"title": "Age 18 to <65 years of age", "categories": [{"measurements": [{"groupId": "BG000", "value": "44.22", "spread": "12.12"}]}]}, {"title": "Age \u2265 65 years of age", "categories": [{"measurements": [{"groupId": "BG000", "value": "70.43", "spread": "4.77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "178"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "94"}]}]}]}, {"title": "Number of Participants with Asthma and Chronic Obstructive Pulmonary Disease (COPD)", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Asthma", "categories": [{"measurements": [{"groupId": "BG000", "value": "222"}]}]}, {"title": "Chronic Obstructive Pulmonary Disease (COPD)", "categories": [{"measurements": [{"groupId": "BG000", "value": "50"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Overall Discrepancy Rate", "description": "Overall discrepancies refer to the difference between the participant-recorded number of actuations and the participant-recorded dose counter readout across the 4-week Treatment Period. The Overall Discrepancy Rate was calculated as 100 multiplied by the total number of discrepancies across all participants who used at least 90% of the labeled actuations divided by the total number of actuations in the same participant population (Completer Population).", "populationDescription": "Completer population, defined as participants who recorded use of at least 90% of the labeled actuations during the 4-week Treatment Period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Overall discrepancies per 100 actuations", "timeFrame": "4-week Treatment Period", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg BID (With Dose Counter)", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of 50/5 mcg, twice a day) over a 4-week Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.13"}]}]}]}, {"type": "PRIMARY", "title": "Overall Quartile Discrepancy Rate", "description": "Quartile discrepancies refer to the difference between\n\nthe participant-recorded number of actuations and the participant-recorded\n\ncounter readout at each of the 4 weekly visit intervals \\[ie, quartiles\\] to\n\nevaluate whether there was any difference in agreement over the life of\n\nthe inhaler. The Quartile Discrepancy Rate was calculated as 100 multiplied by the total number of discrepancies per Quartile across all participant who used at least 90% of the labeled actuations divided by the total number of actuations per Quartile in the same population.", "populationDescription": "Completer Population, defined as participants who had recorded use of at least 90% of the labeled actuations during the 4-week Treatment Period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "discrepancies per 100 actuations", "timeFrame": "4-week Treatment Period", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg BID (With Dose Counter)", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of 50/5 mcg, twice a day) over a 4-week Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.13"}]}]}]}, {"type": "PRIMARY", "title": "Overall Discrepancy Size", "description": "Discrepancy Size refers to the magnitude of the discrepancy between the dose counter readout and the number of recorded actuations (definition of discrepancy). Overall Discrepancy Size was calculated as 100 multiplied by the sum of the absolute values from each Dose Counter Discrepancy Size across all participants who used at least 90% of the labeled actuations divided by the total number of recorded actuations in the same participant population.", "populationDescription": "Completer Population, defined as participants who had recorded use of at least 90% of the labeled actuations during the 4-week Treatment Period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Discrepancy Size Per 100 actuations", "timeFrame": "4-week Treatment Period", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg BID (With Dose Counter)", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of 50/5 mcg, twice a day) over a 4-week Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.14"}]}]}]}, {"type": "PRIMARY", "title": "End of Use Agreement: Number of Inhalers With an End of Use Agreement of 0 (Completer Population)", "description": "The difference in the final MDI dose counter readout and the total number of recorded actuations at the end-of-use. Dose Counter end-of-use agreement was calculated as the sum of the absolute difference between the final dose counter readout and the number of recorded actuations across all participants who used at least 90% of the labeled actuations (excluding participants who used the inhaler beyond the labeled number of actuations) divided by the total number of participants in this population. No participant used more than two inhalers during the treatment period.", "populationDescription": "Completer Population, excluding 2 participants who used more than the labeled number of actuations.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of inhalers", "timeFrame": "4-week Treatment Period", "groups": [{"id": "OG000", "title": "MF/F MDI 100/10 mcg BID (With Dose Counter)", "description": "MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of 50/5 mcg, twice a day) over a 4-week Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "233"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "175"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "6 weeks", "description": "Participants received open-label MF/F 100/10 mcg BID during the 2-week\n\nScreening Period and the 4-week Treatment Period. All participants who received at least one dose of MF/F were included in the safety analysis.", "eventGroups": [{"id": "EG000", "title": "MF/F MDI 100/10 mcg BID", "description": "Included all participants that received 100/10 mcg BID (with and without dose counter)", "seriousNumAffected": 1, "seriousNumAtRisk": 272, "otherNumAffected": 0, "otherNumAtRisk": 272}], "seriousEvents": [{"term": "Oedema Peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 272}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The investigator agrees not to publish/present any interim results without prior sponsor written consent. The investigator agrees to provide to the sponsor, 45 days prior to submission, review copies for publication that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor, prior to submission for publication, to discuss and resolve any such issues/disagreement."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp and Dohme Corp.", "email": "clinicaltrialsresultsdisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M23449", "name": "Pulmonary Disease, Chronic Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "D000068759", "term": "Formoterol Fumarate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "Tea", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}